|
Aug 6
|
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
|
|
Aug 6
|
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales
|
|
Aug 6
|
Novavax lifts 2025 revenue outlook after FDA milestone payment
|
|
Aug 6
|
Novavax banks on vaccine supply partnerships to boost 2025 revenue
|
|
Aug 6
|
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
|
|
Aug 6
|
US Health Department Ending Federal mRNA Vaccine Development
|
|
Aug 6
|
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
|
|
Aug 5
|
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Aug 4
|
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
|
|
Aug 4
|
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
|
|
Aug 4
|
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi
|
|
Aug 1
|
Health Care Roundup: Market Talk
|
|
Aug 1
|
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
|
|
Aug 1
|
Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.
|
|
Aug 1
|
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
|
|
Aug 1
|
Regeneron posts better-than-expected Q2 results, downplays tariff impact
|
|
Aug 1
|
Reddit, Coinbase, Novo Nordisk - Trending Stocks
|
|
Aug 1
|
Regeneron shares edge higher as second quarter earnings surpass estimates
|
|
Aug 1
|
Regeneron Reports Second Quarter 2025 Financial and Operating Results
|
|
Aug 1
|
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
|